期刊文献+

卵巢上皮性癌组织eIF-4A蛋白表达临床意义研究 被引量:4

Expression of eIF-4Ain epithelial ovarian carcinoma and its clinical significance
原文传递
导出
摘要 目的:探讨真核细胞翻译起始因子eIF-4A在卵巢上皮性癌组织中的表达及其临床意义。方法:选取青岛大学医学院附属医院妇科2008-01-01-2012-12-31住院病例。应用免疫组织化学方法测定41例卵巢上皮性癌组织、23例交界性卵巢上皮性肿瘤组织、25例良性卵巢上皮性肿瘤组织及30例正常卵巢组织中eIF-4A蛋白的表达情况。结果:eIF-4A蛋白在正常卵巢组织(3.33%)和卵巢交界性肿瘤组织(60.87%)中阳性表达率差异有统计学意义,z=4.607,P<0.001;在卵巢良性肿瘤组织(12.00%)及卵巢交界性肿瘤组织中的阳性表达率差异有统计学意义,z=3.638,P<0.001;在卵巢交界性肿瘤组织和卵巢上皮性癌组织(87.80%)中阳性表达率差异有统计学意义,z=2.399,P=0.016。卵巢良性肿瘤组织和正常卵巢组织中eIF-4A蛋白的表达差异无统计学意义,z=1.239,P=0.215。eIF-4A蛋白在卵巢上皮性癌组织中的阳性表达与FIGO手术病理分期(χ2=7.080,P=0.020)、组织分级(P=0.002)及是否有淋巴结转移(P=0.008)呈明显的相关性;与患者的年龄(χ2=0.035,P=1.00)及卵巢上皮癌的病理类型(χ2=0.093,P=1.00)无明显的相关性。结论:eIF-4A可能参与卵巢上皮性癌的发生、发展并参与淋巴结转移过程,eIF-4A蛋白可能成为治疗卵巢上皮性癌的一个潜在的分子靶点。 OBJECTIVE: To explore the expression and clinical significance of eIF-4A in epithelial ovarian carcinoma tissues. METHODS:The hospitalized cases were selected from 2008-01-01 to 2012-12-31 in Department of Gyrecology,Affiliated Hospital of Medical College of Qingdao University. The expression of eIF-4A was detected by immunohistochemical method of SP in 41 cases of epithelial ovarian cancer,23 cases of the borderline epithelial neoplasia,25 cases of the benign epithelial neoplasia and 30 cases of normal ovarian tissue. RESULTS: The positive rates of eIF4A were 3.33% and 60.87 % respectively and showed significant statistical difference(z= 4. 607, P〈0. 001) in normal ovarian tissues and borderline epithelial neoplasia groups. It had the same results in benign epithelial neoplasia groups and borderline epithelial neoplasia groups,12.00% and 60.87% (z= 3. 638, P〈0. 001). The expressions of eIF-4A in epithelial ovarian cancer groups were significantly higher than that in borderline epithelial neoplasia groups (z=2. 399, P= 0. 016). The positive rates of eIF4A in normal ovarian tissues and benign epithelial neoplasia groups were 3.33% and 12.00% respectively and had no significant statistical difference(z= 1. 239, P= 0. 215). The positive expression of eIF-4A was significantly related to the later FIGO stage(X2 =7. 080,P=0. 020) ,differentiation of tumor(P=0. 002) and lymph node metastasis of epithelial ovarian carcinoma(P=0. 008), but it had no significant correlation with age( X2 = 0. 035, P = 1.00) and the his topathological types(X2 = 0. 093, P= 1.00). CONCLUSIONS: The positive expression of eIF-4A may play a role in the oncogenesis and malignant progression of epithelial ovarian carcinoma. It may be one of useful molecular markers for diagnosis,identifying cancer and predicting malignant progression of epithelial ovarian carcinoma.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2014年第15期1164-1167,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 卵巢肿瘤 卵巢上皮性癌 真核起始因子4A 免疫组织化学 ovarian neoplasms epithelial ovarian carcinoma eukaryotic translation initation factor 4A immunohistochemical method
  • 相关文献

参考文献15

  • 1鲁强,张志磊,邹存华,付婷婷,马德花,赵淑萍.卵巢上皮性肿瘤组织ATM基因表达缺失及其临床意义的探讨[J].中华肿瘤防治杂志,2011,18(10):799-801. 被引量:7
  • 2Zhou S, Wang GP, Liu C, et al. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis: prognostic markers for breast cancer [J]. BMC cancer,2006,6(1):231.
  • 3强春香,刘渊勇.卵巢癌组织IGF-1表达及其与凋亡和侵袭相关性分析[J].中华肿瘤防治杂志,2013,20(3):210-213. 被引量:7
  • 4Jin C, Rajabi H, Rodrigo CM, et al. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein [J]. On-cogene,2012,32(17):2179-2188.
  • 5曹世姣,张广亮,喻芳,叶柳青,夏伟兰.子宫内膜癌中elF4E与VEGF的表达及其临床意义[J].中国癌症杂志,2012,22(2):120-124. 被引量:9
  • 6Freire ER, Dhalia R, Moura D, et al. The four trypanosomatid elF4E homologues fall into two separate groups, with distinct features in primary sequerce and hio[ogieM properties[-J]. Mol Biochem Parasitol,2011,176(1) :25-36.
  • 7Barhoumi M,Meddeb-Gamaoui A,Tanner NK,et al. DEAD-box pro- teins,like Leishmania elF4A, modulate interleukin (IL)-12, IL-10 and turnout necrosis faetor-alpha production by human monocytes [J]. Parasite Immunol,2013,35(5-6) :194-199.
  • 8Waters LC,Strong SL, Ferlemann E, et al. Structure of the tan- dem MA-3 region of pdcd4 protein and characterization of its in- teractions with eIF4A and eIF4G molecular mechanisms of a tumor suppressor [J]. J Biol Chem,2011,286(19) : 17270-17280.
  • 9Feoktistova K,Tuvshintogs E, Do A, et al. Human elF4E pro- motes mRNA restructuring by stimulating eIF4A helicase activi- ty[J]. Proc Nati Acad Sei,2013,110(33) :13339-13344.
  • 10Akabayov SR, Akabayov B, Richardson CC, et al. Molecular crowding enhanced ATPase activity of the RNA helicase elF4A correlates with compaction of its quaternary structure and association with eIF4G [J]. J Am Chem Soci,2013,135(27) :10040-10047.

二级参考文献66

  • 1Shih I-M, Kurman RJ. Ovarian tumorigenesis:A Proposed model based on morphological and molecular genetic analysis [J]. Am J Pathol,2004,164 (5) :1511- 1518.
  • 2Burger RA. A new model of ovarian carcinogenesis may influence early detection strategies [J]. Am J Obstet Gynecol,2008,198(4):349- 350.
  • 3Kurman RJ, Visvanathan K, Roden R,et al. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based an a new model of carcinogenesis [J]. Am J Obstet Gynecol, 2008,198(4) :351 - 356.
  • 4Seidman JD, Russell P, Kmman RJ. Surface epithelial tumors of the ovary. Blaustein's Pathology of the Female Genital Tract [ M]. Edited by RJ Kurman. New York:Springer Verlag, 2002:791 - 904.
  • 5Singer G,Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma [J]. Am J Pathol,2002,160(4) :1223 - 1228.
  • 6Scully RE. International Histological Classification of Tumors: Histological Typing of Ovarian Tumors [ M]. Geneva, World Health Organization, 1999:12 - 15.
  • 7Scully RE. World Health Organization International Histological Classification of Tumours [M]. New York: Springer, 1999:88- 105.
  • 8Ortiz BH, Ailawadi M, Colitti C, et al. Second primary or recurrence? Comparative patterns of p53 and K - ras mutations suggest that serous borderline ovarian tuners and subsequent serous carcinomas are unrelated tumors [J]. Cancer Res,2001,61(19):7264-7267.
  • 9Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high - grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation [J]. Am J Surg Pathol. 2005,29(2) :218 - 224.
  • 10Dehari R, Kurman RJ, Logani S, et al. The development of high - grade serous carcinoma from atypical proliferative (borderline) serous tumors and low- grade micropapillary serous carcinoma: a morphologic and melecular genetic analysis [J]. Am J Surg Pathol. 2007,31 (7) : 1007 - 1012.

共引文献33

同被引文献35

引证文献4

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部